MedTrace Logo

Anti CT-P13 Antibody in Moderate to Severe Inflammatory Bowel Disease

NCT02846961 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 280

Last updated 2021-02-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the development of anti-drug antibody to biosimilar CT-P13 and to assess the change of drug concentration for 1 year in patients with moderately to severe inflammatory bowel disease.

Conditions

Sponsors & Collaborators

  • Kyungpook National University Hospital

    lead OTHER

Principal Investigators

  • Dong Il Park, MD · Sungkyunkwan University

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2019-09-30
Completion
2020-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02846961 on ClinicalTrials.gov